Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.
Dr Reddy’s has added to its senior leadership team by appointing Marc Kikuchi as CEO of North America Generics. With a record number of US launches in Q3, potentially more in store and now a new leader to steer things through, the firm has improved its outlook for a significant revival in earnings. But risks of delays and competition on certain key anticipated launches in 2019 could dull prospects.
The active pharmaceuticals ingredients segment in India appears to be coming into its own, alongside signs of a revival in the overall sales growth of Indian generic firms in FY2019, a study by an Indian investment banking and consulting services firm has indicated.
Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.